Revvity Inc. (NYSE:RVTY) on Monday reported better-than-expected earnings for the fourth quarter.
The company posted fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55. The life sciences and diagnostics company reported sales of $772.06 million, up 6% (+4% organic growth), surpassing the consensus of $761.29 million.
“We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations,” said Prahlad Singh, president and CEO of Revvity. “Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come.”
Revvity forecasts fiscal 2026 adjusted earnings of $5.35-$5.45 per share versus the consensus of $5.32. The company expects sales of $2.96 billion-$2.99 billion versus the consensus of $2.93 billion. The guidance reflects year-over-year growth of 4%-5% and organic growth of 2%-3%.
Revvity shares closed at $107.09 on Monday.
These analysts made changes to their price targets on Revvity following earnings announcement.
- Jefferies analyst Tycho Peterson maintained Revvity with a Hold and raised the price target from $100 to $105.
- Barclays analyst Luke Sergott maintained the stock with an Overweight rating and raised the price target from $115 to $118.
- Wells Fargo analyst Brandon Couillard maintained Revvity with an Equal-Weight rating and raised the price target from $107 to $110.
- Evercore ISI Group analyst Vijay Kumar maintained the stock with an Outperform rating and boosted the price target from $112 to $118.
Considering buying RVTY stock? Here’s what analysts think:
Photo via Shuttterstock
Recent Comments